Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefania Mosconi

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 11, 2008
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findingsMario Mandalà, Sandro Barni, Irene Floriani, et al.
The Lancet. Gastroenterology & Hepatology|April 8, 2018
Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trialMichele Reni, Gianpaolo Balzano, Silvia Zanon, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 6, 2013
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II studyStefano Cascinu, Rossana Berardi, Alberto Sobrero, et al.
Oncotarget|September 24, 2015
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenibLuca Faloppi, Maristella Bianconi, Riccardo Giampieri, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 30, 2022
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trialGerardo Rosati, Chiara Alessandra Cella, Luigi Cavanna, et al.
The Oncologist|May 10, 2018
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use ProgramChiara Cremolini, Daniele Rossini, Erika Martinelli, et al.
The Oncologist|December 28, 2020
Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 PandemicAlberto Zambelli, Lorenzo Chiudinelli, Vittoria Fotia, et al.
Clinical Colorectal Cancer|March 19, 2023
Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA TrialDebora Basile, Gerardo Rosati, Francesca Bergamo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trialStefano Cascinu, Rossana Berardi, Roberto Bianco, et al.
Journal for Immunotherapy of Cancer|November 24, 2021
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS studySara Lonardi, Alessandra Anna Prete, Federica Morano, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
European Journal of Cancer (Oxford, England : 1990)|December 11, 2008
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findingsMario Mandalà, Sandro Barni, Irene Floriani, et al.
The Lancet. Gastroenterology & Hepatology|April 8, 2018
Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trialMichele Reni, Gianpaolo Balzano, Silvia Zanon, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 6, 2013
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II studyStefano Cascinu, Rossana Berardi, Alberto Sobrero, et al.
Oncotarget|September 24, 2015
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenibLuca Faloppi, Maristella Bianconi, Riccardo Giampieri, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 30, 2022
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trialGerardo Rosati, Chiara Alessandra Cella, Luigi Cavanna, et al.
The Oncologist|May 10, 2018
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use ProgramChiara Cremolini, Daniele Rossini, Erika Martinelli, et al.
The Oncologist|December 28, 2020
Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 PandemicAlberto Zambelli, Lorenzo Chiudinelli, Vittoria Fotia, et al.
Clinical Colorectal Cancer|March 19, 2023
Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA TrialDebora Basile, Gerardo Rosati, Francesca Bergamo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trialStefano Cascinu, Rossana Berardi, Roberto Bianco, et al.
Journal for Immunotherapy of Cancer|November 24, 2021
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS studySara Lonardi, Alessandra Anna Prete, Federica Morano, et al.
Pageof 3